Please use this identifier to cite or link to this item:
Title: Antibody drug conjugates for glioblastoma: current progress toward clinical use.
Austin Authors: Gan, Hui K ;Parakh, Sagun ;Osellame, Laura D;Cher, Lawrence M ;Uccellini, Anthony;Hafeez, Umbreen ;Menon, Siddharth;Scott, Andrew M 
Affiliation: Cancer Therapies and Biology Group, Centre of Research Excellence in Brain Tumours, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.;Tumour Targeting Program, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.;Medical Oncology, Austin Health, Heidelberg, Victoria, Australia.;La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Wellness and Research Centre
La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia.;Department of Biochemistry and Genetics, School of Agriculture, Biomedicine and Environment, La Trobe University, Victoria, Australia.
Medicine (University of Melbourne)
Medical Oncology
Issue Date: 13-Nov-2023
Date: 2023
Publication information: Expert Opinion on Biological Therapy 2023; 23(11)
Abstract: Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience with ADCs in brain tumors and examines future paths for their use in these tumors. This review will cover all the key classes of ADCs which have been tested in primary brain tumors, including commentary on the major trials to date. The efficacy of these trials, as well as their limitations, will put in context of the overall landscape of drug development in brain tumors. Importantly, this review will summarize key learnings and insights from these trials that help provide the basis for rationale ways in which these drugs can be effectively and appropriate developed for patients with primary brain tumors. ADC development in brain tumors has occurred in two major phases to date. Key learnings from previous trials provide a strong rationale for the continued development of these drugs for primary brain tumors. However, the unique biology of these tumors requires development strategies specifically tailored to maximize their optimal development.
DOI: 10.1080/14712598.2023.2282729
Journal: Expert Opinion on Biological Therapy
PubMed URL: 37955063
ISSN: 1744-7682
Type: Journal Article
Subjects: Gliomas
antibody drug conjugates
blood–brain barrier
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jul 18, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.